Investigational Ebola Vaccine Regimen Shows Immune Response in Kids and Adults

investigational ebola vaccine regimen shows immune response in kids and adults

Sumary of Investigational Ebola Vaccine Regimen Shows Immune Response in Kids and Adults:

  • Johnson (J&J) reported its Ebola vaccine regimen, Ad26.ZEBOV (Zabdeno) and MVA-BN-Filo (Mvabea), generated humoral immune responses in adults and children, ages 1-17, with the immune responses persisting in adults for at least two years.
  • This data comes from the phase 3 EBOVAC-Salone clinical study which was conducted in Sierra Leone and the results were published in The Lancet Infectious Diseases.
  • Johnson Vice Chairman of the Executive Committee and Chief Scientific Officer Paul Stoffels, MD, said in a statement.
  • Phase 3 Study ParametersThis study was conducted to determine the safety and immunogenicity of the two-dose, heterologous vaccine regimen.
  • Consenting adults participating in stage one of the study were administered a booster dose of A26.ZEBOV two years after the first dose.
  • “Vaccine-induced humoral immune responses were observed in 41 (98%) of 42 stage 1 participants (geometric mean binding antibody concentration 4784 ELISA units [EU]/mL [95% CI 3736–6125]) and in 176 (98%) of 179 stage 2 participants (3810 EU/mL [3312–4383]) at 21 days after the second vaccination,” the investigators wrote in the study.
  • “Recent and ongoing outbreaks in Africa underscore that the threat of Ebola is not going away, which is why we collaborated to develop a vaccine regimen capable of inducing long-term immunity against Ebola and are now working to ensure that it is accessible to people in need,” Stoffels stated.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.